Not currently recruiting at UCSF
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Tina Bhutani
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Tina Bhutani
I am a dermatologist and clinical researcher in the Department of Dermatology at UCSF. I serve as co-director of the Psoriasis and Skin Treatment Center, a world-renowned clinic dedicated to the care of patients with psoriasis.
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
- ID
- NCT05369403
- Phase
- Phase 3 Atopic Dermatitis (Eczema) Research Study
- Study Type
- Interventional
- Participants
- Expecting 120 study participants
- Last Updated